nsc 664704 has been researched along with Breast Neoplasms in 2 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HM | 1 |
| Kim, CS | 1 |
| Lee, JH | 1 |
| Jang, SJ | 1 |
| Hwang, JJ | 1 |
| Ro, S | 1 |
| Choi, J | 1 |
| Brault, L | 1 |
| Migianu, E | 1 |
| Néguesque, A | 1 |
| Battaglia, E | 1 |
| Bagrel, D | 1 |
| Kirsch, G | 1 |
2 other studies available for nsc 664704 and Breast Neoplasms
| Article | Year |
|---|---|
CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzazepines; Breast Neoplasms; Cell Line, Tumor; Cell Survival; C | 2013 |
New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells.
Topics: Benzazepines; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; | 2005 |